Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective diligently but unsuccessfully to produce a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the past few shares of mine. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such an extremely promotional image in the Uptick Newswire employment interview that I came away with an inadequate viewpoint of the business.

Irony of irony, my poor impression of the business enterprise has grown steadily, though the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this expertise and linked intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) as well as the very first brand new drug program approval ($5 million), and also royalty payments of five percent of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple indications and numerous therapies, it has this single therapy in addition to a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an active company with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications and multiple presentations.

Can all of it be smoke cigarettes and mirrors? That’s a question I have been asking myself through the very beginning of my interest in this organization. Judging with the multiples of thousands of various commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some might say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *